RxDoctor Payments Data

Lisa Post

General Practice · Bastrop, LANPI 1508848623

Payments from drug & device makers

$574in general payments, 2019–2025

Across 23 payments — averaging $24.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$139
  • Novo Nordisk$125
  • Novartis$51
  • Lilly USA, LLC$31
  • Bayer$31
  • Smith+Nephew$29
  • plus $169 from 9 others

What the payments were for

  • Food & beverage$574100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$574 in reported general payments places this provider in the 65th percentile of 1,221 general practice providers in Louisiana.

See all general practice providers in Louisiana

Medicare billing

Part B allowed, 2024
$310,487
Medicare patients
665
Services billed
4,309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban128$60,064
JardianceEmpagliflozin66$47,564
MounjaroTirzepatide36$37,090
OzempicSemaglutide37$36,777
RybelsusSemaglutide18$26,127
VraylarCariprazine Hcl16$22,559
XareltoRivaroxaban37$20,818
LinzessLinaclotide26$18,573
FarxigaDapagliflozin Propanediol21$14,061
EntrestoSacubitril/Valsartan17$8,475
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,318
Tresiba Flextouch U-200Insulin Degludec13$8,025
TradjentaLinagliptin12$7,475
MyrbetriqMirabegron11$6,551
JanuviaSitagliptin Phosphate17$5,884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$125$62,90355 claims
PfizerEliquis$16$60,064128 claims
AbbVieVraylar, Linzess$139$41,13242 claims
Lilly USA, LLCMounjaro$31$37,09036 claims
AstraZenecaFarxiga$25$14,06121 claims
NovartisEntresto$51$8,47517 claims
GSKTrelegy Ellipta$18$8,31811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,221 general practice providers in Louisiana.

Other general practice in Bastrop

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →